Pharmaceutical preparations and methods for inhibiting tumors
View Patent ↗The invention provides pharmaceutical compositions and method for inhibiting growth of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH). In one embodiment the pharmaceutical composition includes human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof. In another embodiment, the pharmaceutical composition includes a mixture of human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof and an anticancer drug which may be administered in an appropriate dosage form, dosage quantity and dosage regimen to a patient suffering from, for example of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, benign prostate hyperplasia, or (BPH) gastrointestinal cancer. The anticancer drug of the latter mixture may be one selected from the group of drugs including mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexate, adriamycin, daunomycin, taxol, taxol derivative, and mixtures thereof.
1. A polypeptide comprising at least two repetitions of the amino acid sequence consisting of SEQ ID NO: 5, wherein the polypeptide inhibits the growth of prostatic adenocarcinoma.
2. A pharmaceutical composition comprising:
a) the polypeptide of claim 1 ; and
b) a pharmaceutically acceptable carrier.
3. The pharmaceutical composition of claim 2 , further comprising an anticancer drug for the treatment of prostatic adenocarcinoma.
4. The pharmaceutical composition of claim 3 , wherein said anticancer drug is selected from the group consisting of mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexate, adriamycin, daunomycin, taxol, taxotere taxane, and mixtures thereof.
5. A method of treating a patient having prostatic adenocarcinoma, the method comprising administering the pharmaceutical composition of claim 2 .
6. A polypeptide of at least 15 and no more than 64 contiguous amino acids of SEQ ID NO: 1, wherein the polypeptide inhibits the growth of prostatic adenocarcinoma, wherein the polypeptide comprises SEQ ID NO: 5.
7. A pharmaceutical composition comprising:
a) the polypeptide of claim 6 ; and
b) a pharmaceutically acceptable carrier.
8. The pharmaceutical composition of claim 7 , further comprising an anticancer drug for the treatment of prostatic adenocarcinoma.
9. The pharmaceutical, composition of claim 8 , wherein said anticancer drug is selected from the group consisting of mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexate, adriamycin, daunomycin, taxol, taxotere, taxane, and mixtures thereof.
10. A method of treating a patient having prostatic adenocarcinoma, the method comprising administering the pharmaceutical composition of claim 7 .
11. A polypeptide consisting of the amino acid sequence defined in SEQ ID NO.:5.
12. A pharmaceutical composition comprising:
a) the polypeptide of claim 11 ; and
b) a pharmaceutically acceptable carrier.
13. The pharmaceutical composition of claim 12 , further comprising an anticancer drug for the treatment of prostatic adenocarcinoma.
14. The pharmaceutical composition of claim 13 , wherein said anticancer drug is selected from the group consisting of mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexate, adriamycin, daunomycin, taxol, taxotere, taxane, and mixtures thereof.
15. A method of treating a patient having prostatic adenocarcinoma, the method comprising administering the pharmaceutical composition of claim 12 .
16. A polypeptide as defined in any one of SEQ ID NO.:10, SEQ ID NO.:11, SEQ ID NO.:12, SEQ ID NO.:13, SEQ ID NO.:14, SEQ ID NO.:15, SEQ ID NO.:16, SEQ ID NO.:17, SEQ ID NO.:18, SEQ ID NO.:19, SEQ ID NO.:20, SEQ ID NO.:21, SEQ ID NO.:22, SEQ ID NO.:23, SEQ ID NO.:24, SEQ ID NO.:25, SEQ ID NO.:26, SEQ ID NO.:27, SEQ ID NO.:28, SEQ ID NO.:29, SEQ ID NO.:30, SEQ ID NO.:31, SEQ ID NO.:32, SEQ ID NO.:33, SEQ ID NO.:34, SEQ ID NO.:35, SEQ ID NO.:36, SEQ ID NO.:37, SEQ ID NO.:38, SEQ ID NO.:39, SEQ ID NO.:40, SEQ ID NO.:41, SEQ ID NO.:42, SEQ ID NO.:43, SEQ ID NO.:44, SEQ ID NO.:45, SEQ ID NO.:46, SEQ ID NO.:47, SEQ ID NO.:48, SEQ ID NO.:49, SEQ ID NO.:50, SEQ ID NO.:51, SEQ ID NO.:52, SEQ ID NO.:53, SEQ ID NO.:54, SEQ ID NO.:55, SEQ ID NO.:56, SEQ ID NO.:57, SEQ ID NO.:58, SEQ ID NO.:59, SEQ ID NO.:60, SEQ ID NO.:61, SEQ ID NO.:62, SEQ ID NO.:63, SEQ ID NO.:64, SEQ ID NO.:65, SEQ ID NO.:66, SEQ ID NO.:67, SEQ ID NO.:68, SEQ ID NO.:69, SEQ ID NO.:70, SEQ ID NO.:71, SEQ ID NO.:72, SEQ ID NO.:73, SEQ ID NO.:74, SEQ ID NO.:75, SEQ ID NO.:76, SEQ ID NO.:77, SEQ ID NO.:78, SEQ ID NO.:79, SEQ ID NO.:80, SEQ ID NO.:81, SEQ ID NO.:82, SEQ ID NO.:83, SEQ ID NO.:84, SEQ ID NO.:85, SEQ ID NO.:86, SEQ ID NO.:87, SEQ ID NO.:88, SEQ ID NO.: 90, SEQ ID NO.: 91 and SEQ ID NO.: 92.
17. A pharmaceutical composition comprising:
a) the polypeptide of claim 16 ; and
b) a pharmaceutically acceptable carrier.
18. The pharmaceutical composition of claim 17 , further comprising an anticancer drug for the treatment of prostatic adenocarcinoma.
19. The pharmaceutical composition of claim 18 , wherein said anticancer drug is selected from the group consisting of mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexate, adriamycin, daunomycin, taxol, taxotere taxane, and mixtures thereof.
20. A method of treating a patient having prostatic adenocarcinoma, the method comprising administering the pharmaceutical composition of claim 17 .
21. A polypeptide which inhibits the growth of prostatic adenocarcinoma, said polypeptide having at least 50% of its amino acid sequence identical to the amino acid sequence consisting of SEQ ID NO: 5.
22. A pharmaceutical composition comprising:
a) the polypeptide of claim 21 ; and
b) a pharmaceutically acceptable carrier.
23. The pharmaceutical composition of claim 22 , further comprising an anticancer drug for the treatment of prostatic adenocarcinoma.
24. The pharmaceutical composition of claim 23 , wherein said anticancer drug is selected from the group consisting of mitomycin, idarubicin cisplatin, 5-fluoro-uracil, methotrexate, adriamycin, daunomycin, taxol, taxotere taxane, and mixtures thereof.
25. A method of treating a patient having prostatic adenocarcinoma, the method comprising administering the pharmaceutical composition of claim 22 .
26. A polypeptide which inhibits the growth of prostatic adenocarcinoma, said polypeptide having at least 70% of its amino acid sequence identical to the amino acid sequence consisting of SEQ ID NO: 5.
27. A pharmaceutical composition comprising:
a) the polypeptide of claim 26 ; and
b) a pharmaceutically acceptable carrier.
28. The pharmaceutical composition of claim 27 , further comprising an anticancer drug for the treatment of prostatic adenocarcinoma.
29. The pharmaceutical composition of claim 28 , wherein said anticancer drug is selected from the group consisting of mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexate, adriamycin, daunomycin, taxol, taxotere, taxane, and mixtures thereof.
30. A method of treating a patient having prostatic adenocarcinoma, the method comprising administering the pharmaceutical composition of claim 27 .
31. A polypeptide which inhibits the growth of prostatic adenocarcinoma, said polypeptide having at least 90% of its amino acid sequence identical to the amino acid sequence consisting of SEQ ID NO: 5.
32. A pharmaceutical composition comprising:
a) the polypeptide of claim 31 ; and
b) a pharmaceutically acceptable carrier.
33. The pharmaceutical composition of claim 32 , further comprising an anticancer drug for the treatment of prostatic adenocarcinoma.
34. The pharmaceutical composition of claim 33 , wherein said anticancer drug is selected from the group consisting of mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexate, adriamycin, daunomycin, taxol, taxotere, taxane, and mixtures thereof.
35. A method of treating a patient having prostatic adenocarcinoma, the method comprising administering the pharmaceutical composition of claim 32 .